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Crimean-Congo hemorrhagic fever
The Perspective ‘‘Ribavirin is not effective against Crimean-
Congo hemorrhagic fever: observations from the Turkish experi-
ence’’ by Ceylan et al.,1 published in this Journal, reﬂected the
‘against’ side of a debate performed in ‘for and against’, or ‘pro et
contra’ style that took place in Istanbul in May 2012. The debate
concerned the use of ribavirin in Crimean-Congo hemorrhagic
fever (CCHF). I was coaching the pro-ribavirin group. From my
observations, at the end of the talk, a consensus was reached on the
use of ribavirin in post-exposure prophylaxis (PEP), such as after a
needle-stick injury of a healthcare worker (HCW). As a result, the
question arose: If we use ribavirin for PEP, then why not give it for
treatment? I will explain the evidence.
Many studies have previously shown the beneﬁcial effects of
ribavirin, despite the lack of power, and the beneﬁt has also been
shown in a recent powerful study.2
The authors of the Perspective claimed that ribavirin therapy
has not been shown to decrease the case-fatality rate (CFR) in
Turkey. The published evidence is against this claim.2–6 Further,
some of the studies cited by the authors in their references list are
in favor of the use of ribavirin, including those published by our
group.7,8 One study against ribavirin was severely biased, and
moreover some of the authors of that biased study were not in
agreement with what was written – an editorial has already been
published.9
Performing a randomized clinical trial (RCT) to examine the role
of ribavirin in CCHF is in contravention to the Declaration of
Helsinki.10 Despite this fact, an RCT has been performed.11 This RCT
was biased, because it included late cases. Ribavirin may not be
beneﬁcial at the late stage of the disease.2 Further, the sample size
was not calculated.
In another biased study referred to by the authors, oral ribavirin
was not given to CCHF patients and a CFR of 5% was reported.12
However, in another study carried out in a similar setting, the CFR
was 2.9% with the use of early ribavirin.3 The 5% fatality rate cannot
be accepted as normal.
Although the authors mentioned the renal and hepatic side
effects of ribavirin in the biased study,9 they did not report the
number of patients who experienced these side effects.
In summary, ribavirin has been found to be effective in the
treatment of CCHF2 and as post-exposure prophylaxis,4 and should
be given as early as possible.2–4 If the physicians who are againsthttp://dx.doi.org/10.1016/j.ijid.2014.08.016
1201-9712/ 2014 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).the use of ribavirin were to be infected with the CCHF virus (which
I sincerely hope never occurs), would they reject ribavirin
treatment? Then, remember the Hippocratic Oath: primum non
nocere. So, why not give this treatment to the patients?
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